LGI1 Antibody

Product Specifications

Background

LGI1 Antibody: The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist; this LGI1 antibody will recognize only the longer form.

NCBI Gene ID

9211

Swiss Prot

O95970

Accession Number

AAQ89244

Host

Rabbit

Reactivity

Human, Mouse, Rat

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Neuroscience

Purification

LGI1 Antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1201 - HeLa Cell Lysate

Concentration

1 mg/mL

Homology

Predicted species reactivity based on immunogen sequence: Bovine: (93%)

Buffer

LGI1 Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

LGI1 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Fragment

IgG

Specificity

This LGI1 antibody is predicted to be specific to LGI1 and not recognize other LGI proteins.

Symbol

LGI1

Positive Control 2

Cat. No. 10-301 - Human Brain Tissue Slide

NCBI Official Name

Leucine-rich, glioma inactivated 1

NCBI Organism

Homo sapiens

Background Reference 01

Chernova OB, Somerville RP and Cowell JK. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene1998; 17:2873-81.

Background Reference 02

Fialka F, Gruber RM, Hitt R, et al. CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma - A pilot study. Oral Oncol.2008

Background Reference 03

Gu W, Gibert Y, Wirth T, et al. Using gene-history and expression analysis to assess the involvement of LGI genes in human disorders. Mol. Biol. Evol.2005; 22:2209-16.

Background Reference 04

Fukata Y, Adesnik H, Iwanaga T, et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science2006; 313:1792-5.